JP2009286804A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009286804A5 JP2009286804A5 JP2009212564A JP2009212564A JP2009286804A5 JP 2009286804 A5 JP2009286804 A5 JP 2009286804A5 JP 2009212564 A JP2009212564 A JP 2009212564A JP 2009212564 A JP2009212564 A JP 2009212564A JP 2009286804 A5 JP2009286804 A5 JP 2009286804A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- protein
- follistatin
- muscular dystrophy
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 25
- 102000016970 Follistatin Human genes 0.000 claims 18
- 108010014612 Follistatin Proteins 0.000 claims 18
- 102000004169 proteins and genes Human genes 0.000 claims 17
- 108090000623 proteins and genes Proteins 0.000 claims 17
- 230000004048 modification Effects 0.000 claims 7
- 238000012986 modification Methods 0.000 claims 7
- 102000019203 Follistatin-Related Proteins Human genes 0.000 claims 6
- 108010012820 Follistatin-Related Proteins Proteins 0.000 claims 6
- 208000021642 Muscular disease Diseases 0.000 claims 6
- 208000030159 metabolic disease Diseases 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 201000006938 muscular dystrophy Diseases 0.000 claims 4
- 206010028289 Muscle atrophy Diseases 0.000 claims 3
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 201000000585 muscular atrophy Diseases 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 2
- 108010088751 Albumins Proteins 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102000004472 Myostatin Human genes 0.000 claims 2
- 108010056852 Myostatin Proteins 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000035810 Denervation atrophy Diseases 0.000 claims 1
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 206010028372 Muscular weakness Diseases 0.000 claims 1
- 206010028424 Myasthenic syndrome Diseases 0.000 claims 1
- 206010028629 Myoglobinuria Diseases 0.000 claims 1
- 201000009623 Myopathy Diseases 0.000 claims 1
- 208000010316 Myotonia congenita Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 201000006793 Walker-Warburg syndrome Diseases 0.000 claims 1
- 210000001766 X chromosome Anatomy 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical group 0.000 claims 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000011474 congenital myopathy Diseases 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 201000009338 distal myopathy Diseases 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 206010016208 familial periodic paralysis Diseases 0.000 claims 1
- 230000004927 fusion Effects 0.000 claims 1
- 230000013595 glycosylation Effects 0.000 claims 1
- 238000006206 glycosylation reaction Methods 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000025855 muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4 Diseases 0.000 claims 1
- 230000036473 myasthenia Effects 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 206010030875 ophthalmoplegia Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000017854 proteolysis Effects 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 claims 1
- 230000001148 spastic effect Effects 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35784602P | 2002-02-21 | 2002-02-21 | |
| US43464502P | 2002-12-20 | 2002-12-20 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Division JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009286804A JP2009286804A (ja) | 2009-12-10 |
| JP2009286804A5 true JP2009286804A5 (OSRAM) | 2010-10-21 |
Family
ID=27767537
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Expired - Fee Related JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
| JP2009212564A Pending JP2009286804A (ja) | 2002-02-21 | 2009-09-14 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003571402A Expired - Fee Related JP4429728B2 (ja) | 2002-02-21 | 2003-02-21 | フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US7572763B2 (OSRAM) |
| EP (1) | EP1572934A4 (OSRAM) |
| JP (2) | JP4429728B2 (OSRAM) |
| KR (1) | KR20040096592A (OSRAM) |
| AU (1) | AU2003216345A1 (OSRAM) |
| BR (1) | BR0307871A (OSRAM) |
| CA (1) | CA2476654A1 (OSRAM) |
| MX (1) | MXPA04008149A (OSRAM) |
| NO (1) | NO20043564L (OSRAM) |
| PL (1) | PL374966A1 (OSRAM) |
| WO (1) | WO2003072714A2 (OSRAM) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200526779A (en) * | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| US7192717B2 (en) * | 2002-02-21 | 2007-03-20 | Wyeth | GASP1: a follistatin domain containing protein |
| CA2476654A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| DE60331778D1 (de) * | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| ES2565496T3 (es) * | 2003-01-14 | 2016-04-05 | Dana-Farber Cancer Institute | Sensibilizador a la terapia para el cáncer |
| RU2322261C2 (ru) | 2003-06-02 | 2008-04-20 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
| US20060241035A1 (en) * | 2003-07-11 | 2006-10-26 | Daria Onichtchouk | Use of dg153 secreted protein products for preventing and treating pancreatic disease and/or obesity and/or metabolic syndrome |
| JP2007526337A (ja) | 2004-03-02 | 2007-09-13 | アクセルロン ファーマ インコーポレーテッド | Ａｌｋ７およびミオスタチン阻害剤ならびにその使用 |
| US8420603B2 (en) * | 2004-05-14 | 2013-04-16 | Abraxis Bioscience, Llc | SPARC and methods of use thereof |
| AU2006249235B2 (en) | 2004-05-14 | 2010-11-11 | Abraxis Bioscience, Llc | Sparc and methods of use thereof |
| WO2005115439A2 (en) * | 2004-05-27 | 2005-12-08 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
| US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| JP2008509927A (ja) * | 2004-08-12 | 2008-04-03 | ワイス | Ｇｄｆ−８阻害剤を使用する、糖尿病、肥満、および心臓血管疾患のための併用療法 |
| TWI384069B (zh) | 2004-08-27 | 2013-02-01 | Pfizer Ireland Pharmaceuticals | 多胜肽之製法 |
| US7335491B2 (en) | 2004-08-27 | 2008-02-26 | Wyeth Research Ireland Limited | Production of anti-abeta |
| TWI364458B (en) | 2004-08-27 | 2012-05-21 | Wyeth Res Ireland Ltd | Production of tnfr-lg |
| NZ538097A (en) * | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| WO2006107611A2 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
| US20060240487A1 (en) * | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of GDF-8 modulating agents |
| PL2407486T3 (pl) | 2005-08-19 | 2018-05-30 | Wyeth Llc | Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8 |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| EP1998796A2 (en) * | 2006-03-28 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Gdf-9/bmp-15 modulators for the treatment of bone disorders |
| CA2671983A1 (en) | 2006-12-08 | 2009-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI432449B (zh) | 2007-02-02 | 2014-04-01 | Acceleron Pharma Inc | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| KR20220002710A (ko) | 2008-06-26 | 2022-01-06 | 악셀레론 파마 인코포레이티드 | 액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US20130150554A1 (en) | 2010-08-20 | 2013-06-13 | Wyeth Llc | Cell culture of growth factor-free adapted cells |
| JP6400473B2 (ja) | 2011-10-21 | 2018-10-03 | ファイザー・インク | 細胞培養を改善するための鉄の添加 |
| US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
| SA113340642B1 (ar) | 2012-06-15 | 2015-09-15 | فايزر إنك | أجسام مضادة معارضة محسنة ضد gdf-8 واستخداماتها |
| CA2880649C (en) | 2012-08-01 | 2023-03-14 | Elizabeth MCNALLY | Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (ltbp4) |
| CN112957462A (zh) | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血的方法 |
| JP6401171B2 (ja) * | 2012-10-24 | 2018-10-03 | セルジーン コーポレイション | 貧血の治療に使用するためのバイオマーカー |
| MX366336B (es) | 2012-11-02 | 2019-07-05 | Celgene Corp | Antagonistas de activina - actrii y usos para el tratar trastornos oseos y otros. |
| AU2014209178B2 (en) | 2013-01-25 | 2018-11-08 | Takeda Pharmaceutical Company Limited | Follistatin in treating Duchenne muscular dystrophy |
| JP2014151438A (ja) * | 2013-02-04 | 2014-08-25 | Koito Mfg Co Ltd | レーザー溶着方法 |
| GB201308117D0 (en) * | 2013-05-06 | 2013-06-12 | Univ Leuven Kath | Inhibitor of calcifying disorders |
| US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
| KR102305109B1 (ko) | 2014-06-04 | 2021-09-27 | 악셀레론 파마 인코포레이티드 | 폴리스타틴 폴리펩티드를 이용한 장애의 치료방법 및 치료를 위한 조성물 |
| CN107636154A (zh) | 2015-03-26 | 2018-01-26 | 阿塞勒隆制药公司 | 促滤泡素抑制素相关的融合蛋白及其用途 |
| MX2019001043A (es) | 2016-07-27 | 2019-09-26 | Acceleron Pharma Inc | Metodos y composiciones para el tratamiento de la mielofibrosis. |
| WO2018218273A1 (en) * | 2017-05-29 | 2018-12-06 | Paranta Biosciences Limited | Method of treating hypertension and kidney disease |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| AU2019224003A1 (en) * | 2018-02-20 | 2020-10-08 | Epirium Bio Inc. | Compounds and compositions for the treatment of muscular disorders |
| EP3897689B1 (en) | 2018-12-21 | 2025-02-05 | Northwestern University | Use of annexins in preventing and treating muscle membrane injury |
| US20220062299A1 (en) | 2018-12-26 | 2022-03-03 | Northwestern University | Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder |
| MX2019015589A (es) * | 2019-12-19 | 2021-06-21 | Centro De Investig Y Asistencia En Tecnologia Y Diseno Del Estado De Jalisco A C | Molécula sintética de adn con potenciador autorregulado por hipoxia y/o inflamación para uso como agente terapéutico de enfermedades inflamatorias y degeneración tisular. |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0098110B1 (en) | 1982-06-24 | 1989-10-18 | NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD | Long-acting composition |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5116944A (en) | 1989-12-29 | 1992-05-26 | Neorx Corporation | Conjugates having improved characteristics for in vivo administration |
| US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
| DE122004000008I1 (de) * | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| EP0690873B1 (en) | 1993-03-19 | 2003-06-11 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US20030074680A1 (en) * | 1993-03-19 | 2003-04-17 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
| US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
| US6607884B1 (en) * | 1993-03-19 | 2003-08-19 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-8 |
| US6673534B1 (en) * | 1995-10-26 | 2004-01-06 | The Johns Hopkins University School Of Medicine | Methods for detection of mutations in myostatin variants |
| EP0698094B1 (en) | 1993-05-12 | 2004-02-04 | Genetics Institute, LLC | Bmp-11 compositions |
| JPH09501932A (ja) | 1993-08-26 | 1997-02-25 | ジェネティックス・インスティテュート・インコーポレイテッド | ヒト・骨形態形成蛋白を用いる神経再生 |
| US7332575B2 (en) * | 1994-03-18 | 2008-02-19 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptide from aquatic species, and transgenic aquatic species |
| US5914234A (en) | 1994-07-08 | 1999-06-22 | The Johns Hopkins University School Of Medicine | Methods of detecting growth differentiation factor-11 |
| US6008434A (en) | 1994-07-08 | 1999-12-28 | Johns Hopkins University School Of Medicine | Growth differentiation factor-11 transgenic mice |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6548644B1 (en) * | 1997-03-10 | 2003-04-15 | Immunex Corporation | Site protected protein modification |
| US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| CA2302525A1 (en) | 1997-08-29 | 1999-03-04 | Human Genome Sciences, Inc. | Follistatin-3 |
| WO1999024057A2 (en) | 1997-11-07 | 1999-05-20 | Genetics Inst | Neuronal uses of bmp-11 |
| US5942420A (en) * | 1997-11-17 | 1999-08-24 | Millennium Biotherapeutics, Inc. | Molecules of the follistatin-related protein family and uses therefor |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| US6004937A (en) | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
| DE69941116D1 (de) | 1998-05-06 | 2009-08-27 | Metamorphix Inc | G von gdf-8 |
| JP2002523042A (ja) | 1998-08-20 | 2002-07-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｄｃｒ５、ｂｍｐ結合タンパク質、およびそれらの適用 |
| EP1123393A1 (en) * | 1998-10-15 | 2001-08-16 | ZymoGenetics, Inc. | Follistatin-related protein zfsta2 |
| ATE322681T1 (de) | 1999-01-21 | 2006-04-15 | Metamorphix Inc | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| WO2001005998A1 (en) | 1999-07-16 | 2001-01-25 | Human Genome Sciences, Inc. | Follistatin-3 |
| US7098372B1 (en) * | 1999-09-13 | 2006-08-29 | Wyeth | Pharmaceutical compositions and methods of using secreted frizzled related protein |
| JP2003527099A (ja) * | 1999-11-03 | 2003-09-16 | ザイモジェネティクス，インコーポレイティド | フォリスタチン関連タンパク質ｚｆｓｔａ４ |
| WO2001064888A2 (en) | 2000-02-29 | 2001-09-07 | Zymogenetics, Inc. | Kunitz domain polypeptide zkun8 |
| ATE348161T1 (de) * | 2000-03-03 | 2007-01-15 | Curagen Corp | Fctrx genannte proteine und dafür kodierende nuklein säure |
| AU2001266557A1 (en) * | 2000-04-12 | 2001-10-23 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7037501B2 (en) * | 2001-01-04 | 2006-05-02 | Regents Of The University Of Minnesota | Myostatin immnoconjugate |
| TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
| US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
| CA2476654A1 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
| US7192717B2 (en) * | 2002-02-21 | 2007-03-20 | Wyeth | GASP1: a follistatin domain containing protein |
| DE60331778D1 (de) | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
| AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| WO2004058988A2 (en) | 2002-12-20 | 2004-07-15 | Amgen, Inc. | Binding agents which inhibit myostatin |
| US20060240487A1 (en) * | 2005-03-23 | 2006-10-26 | Nowak John A | Detection of GDF-8 modulating agents |
| WO2006107611A2 (en) * | 2005-03-23 | 2006-10-12 | Wyeth | Detection of an immune response to gdf-8 modulating agents |
-
2003
- 2003-02-21 CA CA002476654A patent/CA2476654A1/en not_active Abandoned
- 2003-02-21 JP JP2003571402A patent/JP4429728B2/ja not_active Expired - Fee Related
- 2003-02-21 MX MXPA04008149A patent/MXPA04008149A/es active IP Right Grant
- 2003-02-21 EP EP03743174A patent/EP1572934A4/en not_active Withdrawn
- 2003-02-21 WO PCT/US2003/005150 patent/WO2003072714A2/en not_active Ceased
- 2003-02-21 US US10/369,738 patent/US7572763B2/en not_active Expired - Fee Related
- 2003-02-21 PL PL03374966A patent/PL374966A1/xx not_active Application Discontinuation
- 2003-02-21 KR KR10-2004-7012978A patent/KR20040096592A/ko not_active Withdrawn
- 2003-02-21 AU AU2003216345A patent/AU2003216345A1/en not_active Withdrawn
- 2003-02-21 BR BR0307871-0A patent/BR0307871A/pt not_active IP Right Cessation
-
2004
- 2004-08-26 NO NO20043564A patent/NO20043564L/no not_active Application Discontinuation
-
2009
- 2009-06-02 US US12/476,489 patent/US20100047259A1/en not_active Abandoned
- 2009-09-14 JP JP2009212564A patent/JP2009286804A/ja active Pending
-
2010
- 2010-09-17 US US12/884,371 patent/US20110020372A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009286804A5 (OSRAM) | ||
| JP2005531505A5 (OSRAM) | ||
| JP2010031018A5 (OSRAM) | ||
| US20130137629A1 (en) | Combination treatment for metabolic disorders | |
| JP2011506442A5 (OSRAM) | ||
| JP6755175B2 (ja) | インスリン投薬レジメン | |
| JP2006501820A5 (OSRAM) | ||
| JP2012525844A5 (OSRAM) | ||
| JP2015517459A5 (OSRAM) | ||
| CA3237751A1 (en) | Ionic liquid compositions | |
| JP2007500236A5 (OSRAM) | ||
| RU2011117645A (ru) | Лечение сахарного диабета с использованием инъекций инсулина с частотой менее одного раза в день | |
| RU2014101207A (ru) | Новые показания к применению при лечении антителами против il-1-бета | |
| JP2018504111A (ja) | ＧＬＰ及び免疫グロブリンハイブリッドＦｃ融合ポリペプチド及びその用途 | |
| JP2012520866A5 (OSRAM) | ||
| JP2011500851A5 (OSRAM) | ||
| WO2009139362A1 (ja) | Dpp-iv阻害薬と他の糖尿病治療薬との併用又は組み合せからなる医薬 | |
| TW201733613A (zh) | 用於治療肥胖之升糖素及glp-1共促效劑 | |
| CA2678646A1 (en) | A conjugate of insulin and vitamin b12 for oral delivery | |
| JP2009519949A5 (OSRAM) | ||
| JP2022523972A (ja) | 増殖分化因子１５併用療法 | |
| BR112021006477A2 (pt) | combinação que compreende uma substância com atividade para um receptor de glucagon ou um conjugado do mesmo, kit e composição farmacêutica para prevenir ou tratar doenças | |
| TW202133882A (zh) | 肽與多醣的新共軛物 | |
| JP2006514665A5 (OSRAM) | ||
| JP2014500244A5 (OSRAM) |